Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Metastatic melanoma is the most aggressive form of skin cancer. In an effort to achieve targeted therapy for metastatic melanoma, researchers recently developed a new radioactive drug that emits alpha ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Actinium Pharmaceuticals (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...